Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard medical scale called ECOG, scoring 0 or 1)
- People who have a confirmed diagnosis of hepatocellular carcinoma (a type of liver cancer)
- People whose liver cancer has shown limited progression (spread or growth in 5 or fewer spots in total) while receiving a first-line immunotherapy treatment approved for use in Hong Kong, such as atezolizumab plus bevacizumab, durvalumab plus tremelimumab, durvalumab, nivolumab plus ipilimumab
- People whose progressing tumour(s) are suitable for a precise type of radiation treatment called SBRT, based on specific size and location requirements for both liver and non-liver tumours (confirm with trial site for full technical details)
- People who have previously received radiofrequency ablation (a heat-based tumour treatment) or trans-arterial chemoembolization (a procedure that blocks blood supply to tumours)
- People whose liver is functioning at an acceptable level, as measured by a standard scoring system called Child-Pugh A
- People with a life expectancy of more than 12 weeks
- People who have at least one tumour that can be measured using standard imaging criteria
- People whose blood counts, liver function, and kidney function meet the specific levels required by the trial (confirm with trial site for exact values)
- People who are able to read, understand, and provide written consent to participate
Who may not be able to join:
- People who have had another cancer diagnosis in the past 5 years, other than certain treated skin cancers or cervical pre-cancerous changes
- People who have previously had radiotherapy to the abdomen
- People who have previously received a treatment called yttrium-90 chemoembolization
- People who have had repeated problems with wounds or ulcers that would not heal within the 2 months before joining the trial
- People who are pregnant or breastfeeding at any point during the study
- People who have an active autoimmune disease (where the immune system attacks the body) that has required ongoing treatment within the past 2 years
- People who have been diagnosed with an immune system deficiency, including HIV
- People who are currently taking corticosteroid medication (such as prednisone) at a dose greater than 10mg per day
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 3505 1042
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Progression-free survival (PFS) with the addition of SBRT to oligo-progressive sites
Can't join this trial?
Data last synced from ClinicalTrials.gov: 6 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.